UbC4 from Leishmania is a Druggable E2 Ubiquitin Conjugating Enzyme: Structural Basis and Fragment Hits for Future E2-Recruiting PROTAC Development

Cécile Exertier, Lorenzo Antonelli, Anastasia Liuzzi, Marcus Ruffa, Vittorio Brufani, Gianni Colotti, Annarita Fiorillo, Andrea Ilari · 2026

Read UbC4 from Leishmania is a Druggable E2 Ubiquitin Conjugating Enzyme: Structural Basis and Fragment Hits for Future E2-Recruiting PROTAC Development by Cécile Exertier, Lorenzo Antonelli, Anastasia Liuzzi, Marcus Ruffa, Vittorio Brufani, Gianni Colotti, Annarita Fiorillo, Andrea Ilari (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13613956.txt.

Description

Cecile Exertier and co-authors map a parasite enzyme that could anchor a new class of targeted drugs against leishmaniasis, in a study from 2026. The disease strikes about two million people a year, and current treatments are often toxic or failing to resistance. A drug family called PROTACs destroys chosen proteins by tagging them for the cell's disposal system, which may dodge both problems.

Little was known about that disposal system in the Leishmania parasite. The team solved the structure of one of its tag handling enzymes, called UbC4, and screened small fragments that bind it. Their case is that drug designers can recruit this enzyme directly, since the parasite lacks the usual partner enzymes used in human targeted drugs. Fragment hits give the project its first chemical footholds.

Catalog record

CREATORCécile Exertier, Lorenzo Antonelli, Anastasia Liuzzi, Marcus Ruffa, Vittorio Brufani, Gianni Colotti, Annarita Fiorillo, Andrea Ilari
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13613956

Browse the full library · About the Tower of Babel